Start with the status: this is a proposal
DEA published the notice of proposed rulemaking in the Federal Register on August 11. It would move suvorexant, lemborexant, and daridorexant from federal Schedule IV to Schedule V. The publication is official, but it is not a final rule and it has no effective date. The August 14 edition of 21 CFR 1308.14 still lists all three substances in Schedule IV.
That distinction should survive every handoff. A news alert, vendor ticket, or policy note can say “Schedule V proposed.” It should not shorten that to “Schedule V” or prompt a user to overwrite the current value. The published notice sets September 10, 2026, as the deadline for electronic or postmarked comments; the electronic docket closes at 11:59 p.m. Eastern Time that day.
Match the three substances, not the whole sleep category
The proposed transfer covers suvorexant, lemborexant, and daridorexant, marketed as Belsomra, Dayvigo, and Quviviq, respectively. DEA describes them as the three approved dual orexin receptor antagonists with this exact mechanism. Zolpidem, temazepam, triazolam, and other sleep medicines appear in the agency's comparison evidence, but they are not included in the proposed regulatory text.
For a consultant-pharmacy system, ingredient-level matching is the safer anchor. Brand text can change, a product list may carry more than one label, and a class-level rule would be too broad. Preserve the ingredient, the current federal schedule, the proposed schedule, the docket number DEA-1645, and the source date as separate fields. That makes the status visible without turning a three-substance proposal into a category-wide edit.
Do not invent a federal handling change
The most operationally important sentence in the filing is also the least dramatic: DEA says Schedule IV and Schedule V controlled substances are subject to identical federal regulatory controls and administrative sanctions. The proposal says the transfer would retain the same controls for registration, security, labeling, inventory, records and reports, prescriptions, disposal, manufacturing, distribution, import, export, and liability.
DEA therefore projects no economic impact from the transfer and says it would not add or modify recordkeeping or reporting requirements. That is the agency's conclusion about this federal proposal, not a reason to stop applying current controlled-substance procedures. While the substances remain in Schedule IV, continue the current authorized workflow. If a final rule later moves them, the immediate software task is likely to be a controlled reference-data reconciliation rather than a redesign of federal handling steps.
A lower schedule is not a clinical verdict
DEA and HHS reviewed medical use, abuse potential, dependence liability, surveillance reports, human abuse-potential studies, and comparator substances. The proposal finds a low potential for abuse relative to Schedule IV substances and accepted medical use in the United States. It also describes important limits: use of these drugs is comparatively low, available abuse evidence is limited, and the limited availability of reference material and recently developed detection methods may contribute to underreporting.
Those findings support a scheduling proposal. They do not establish that the medicines have no abuse or misuse risk, that one is preferable for a particular resident, or that an existing indication, monitoring plan, fall-risk review, or deprescribing question can be skipped. Keep the regulatory classification and the resident-specific medication review in different evidence fields.
Use one small ledger instead of a premature policy rewrite
A proportionate tracking record can be short: ingredient and product match; current federal schedule and source edition; proposed schedule and docket; publication status; September 10 comment close; final-rule and effective dates when they exist; applicable state source and date; downstream terminology feed, policy, report, export, and training references; and one owner for reconciliation. Preserve the prior value rather than silently replacing it.
The state line matters because this is a federal Controlled Substances Act proposal. Do not infer the status of an applicable state schedule from the federal headline. If DEA publishes a final rule, verify the final text, its effective date, the then-current federal table, and the relevant state source before releasing a production change. A vendor's terminology update should be checked against those sources, not treated as the legal event itself.
The next check is a final action—not a new workflow
For now, mark the item as proposed, retain Schedule IV as the current federal value, and record September 10 as the comment deadline. A later final rule and effective date would justify a second, dated review. Until then, the calm operational response is enough: keep the status explicit, keep the three ingredients in scope, and leave current handling and resident-review work intact.